Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Toltrazuril
Elanco GmbH
QP51AJ01
Toltrazuril
50 milligram(s)/millilitre
Oral suspension
POM: Prescription Only Medicine as defined in relevant national legislation
toltrazuril
Authorised
2016-11-25
Health Products Regulatory Authority 01 October 2021 CRN00C7NZ Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Baycox Multi 50 mg/ml oral suspension for Cattle, Pigs and Sheep 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE: Toltrazuril 50 mg EXCIPIENTS: Sodium benzoate (E211) 2.1 mg Sodium propionate (E281) 2.1 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral suspension. White or yellowish suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle (calves: dairy calves, beef suckler, bull beef), Pigs (Piglets, 3-5 days old), Sheep (lambs). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Cattle: For the prevention of clinical signs of coccidiosis and reduction of coccidia shedding in calves on farms with a confirmed history of coccidiosis caused by Eimeria bovis or Eimeria zuernii. Pigs: For the prevention of clinical signs of coccidiosis in neonatal piglets (3‑5 days old) on farms with a confirmed history of coccidiosis caused by Cystoisospora suis. Sheep: For the prevention of clinical signs of coccidiosis and reduction of coccidia shedding in lambs on farms with a confirmed history of coccidiosis caused by Eimeria crandallis and Eimeria ovinoidalis. 4.3 CONTRAINDICATIONS Do not use in cases of hypersensitivity to the active substance or to any of the excipients. For further information on use in cattle please refer to the table in section 4.5 Special precautions for use, Other precautions. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES It is recommended to treat all animals in a pen. Hygienic measures may reduce the risk of coccidiosis. It is therefore, recommended to improve concomitantly the hygienic conditions in the concerned facility, particularly dryness and cleanliness. To obtain maximum benefit, animals should be treated before the expected onset of clinical signs, i.e. in the prepatent period. Health Products Regulatory Authority 01 October 2021 CRN00C7NZ Page 2 of 5 To alter the course of a Read the complete document